Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6243529 | 0.81 | CYP1A2 (0.53) | POLBRXFP1HPGDMAPTTDP1 | |
| SCHEMBL29812491 | 0.80 | CYP1A2 (0.61) | POLBHPGDMEN1KMT2AKDM4E | |
| SCHEMBL1157659 | 0.80 | CYP1A2 (0.61) | POLBHPGDMEN1KMT2AKDM4E | |
| SCHEMBL351155 | 0.78 | CYP1A2 (0.50) | POLBHPGDMAPTMEN1KMT2A | |
| SCHEMBL3064663 | 0.76 | FFAR1 (0.54) | MAPTMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL6602505 | 0.76 | POLB (0.50) | POLBRXFP1HPGDMAPTTDP1 | |
| SCHEMBL6602508 | 0.75 | POLB (0.49) | POLBRXFP1HPGDMAPTTDP1 | |
| SCHEMBL22400479 | 0.74 | CYP1A2 (0.46) | POLBHPGDMAPTTDP1MEN1 | |
| SCHEMBL30489905 | 0.74 | CYP1A2 (0.46) | POLBHPGDMAPTTDP1MEN1 | |
| SCHEMBL3077714 | 0.74 | MEN1 (0.61) | POLBRXFP1HPGDTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3297772-A1 | METHOD OF PRETREATMENT FOR ELECTROLESS PLATING | MacDermid, Incorporated (US) | 2018-03-28 | — | — | EP | claimed |
| US-20160348245-A1 | Method of Pretreatment for Electroless Plating | MACDERMID, INCORPORATED | 2016-12-01 | — | — | US | claimed |
| EP-3297772-A1 | METHOD OF PRETREATMENT FOR ELECTROLESS PLATING | MacDermid, Incorporated (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20160348245-A1 | Method of Pretreatment for Electroless Plating | MACDERMID, INCORPORATED | 2016-12-01 | — | — | US | disclosed |
| EP-2188263-B1 | BENZIMIDAZOLE DERIVATIVES USED AS FXR AGONISTS | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-7790904-B2 | Substituted benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090062356-A1 | SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-03-05 | — | — | US | disclosed |
| EP-0783318-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0783318-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5585359-A | LACK OF THIOL MOIETY PREVENTS THIOL-DEPENDENT CHEMICAL REACTIONS AND REDUCES SYSTEMIC TOXICITY | MERCK & CO., INC. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996009836-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062356-A1 | SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | NR1H4, SLC10A1, FXR1 | POLB 3880/4885RXFP1 401/4885HPGD 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.